Mustang Bio stock rockets 580% on blood cancer drug study

seekingalpha06-18

Shares of Mustang Bio (NASDAQ:MBIO) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444757116?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475811936/image_475811936.jpg","is_english":true,"pubTime":"2024-06-18 03:37","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2444757116","market":"sh","top_or_hot":-1,"title":"Mustang Bio stock rockets 580% on blood cancer drug study","media":"seekingalpha","content":"<div>\n<p>Shares of Mustang Bio (NASDAQ:MBIO) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment...</p>\n\n<a href=\"https://seekingalpha.com/news/4116753-mustang-bio-stock-rockets-on-blood-cancer-drug-study\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mustang Bio stock rockets 580% on blood cancer drug study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMustang Bio stock rockets 580% on blood cancer drug study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 03:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4116753-mustang-bio-stock-rockets-on-blood-cancer-drug-study><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Mustang Bio (NASDAQ:MBIO) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment...</p>\n\n<a href=\"https://seekingalpha.com/news/4116753-mustang-bio-stock-rockets-on-blood-cancer-drug-study\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBIO","symbol_name":"Mustang Bio, Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4116753-mustang-bio-stock-rockets-on-blood-cancer-drug-study","article_id":"2444757116","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475811936/image_475811936.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444757116","pubTimestamp":1718653022,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Mustang Bio  rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment of Waldenstrom macroglobulinemia, or WM, a type of non-Hodgkin lymphoma, or NHL. Mustang said the data showed an overall response rate of 90%, with one patient remaining in complete remission at 31 months. All ten patients enrolled in the study had been previously treated with BTKi therapies. It added that outpatient administration of the product was allowed and found to be feasible, according to a statement. The company noted that there are currently no FDA approved CAR-T treatments for WM. The drug is being developed in collaboration with the Fred Hutch Cancer Center for B-cell NHL and chronic lymphocytic leukemia.  Mustang presented the data at the European Hematology Association 2024 Hybrid Congress.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBIO":"Mustang Bio, Inc","BK4139":"生物科技"},"translate_title":"Mustang Bio股价因血癌药物研究飙升580%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBIO":1},"content_text":"Shares of Mustang Bio (NASDAQ:MBIO) rocketed 580% in afternoon trading Monday after the biotech company reported positive data from a Phase 1/2 trial for its CAR-T cell therapy MB-106 in the treatment of Waldenstrom macroglobulinemia, or WM, a type of non-Hodgkin lymphoma, or NHL. Mustang said the data showed an overall response rate of 90%, with one patient remaining in complete remission at 31 months. All ten patients enrolled in the study had been previously treated with BTKi therapies. It added that outpatient administration of the product was allowed and found to be feasible, according to a statement. The company noted that there are currently no FDA approved CAR-T treatments for WM. The drug is being developed in collaboration with the Fred Hutch Cancer Center for B-cell NHL and chronic lymphocytic leukemia.  Mustang presented the data at the European Hematology Association 2024 Hybrid Congress.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444757116"}